SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-20-018032
Filing Date
2020-08-14
Accepted
2020-08-14 16:02:47
Documents
67
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20200630_10q.htm 10-Q 1191454
2 EXHIBIT 10.4 ex_199807.htm EX-10.4 23667
3 EXHIBIT 31.1 ex_198120.htm EX-31.1 9507
4 EXHIBIT 32.1 ex_198121.htm EX-32.1 4922
  Complete submission text file 0001437749-20-018032.txt   6640761

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT navb-20200630.xml EX-101.INS 1333384
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20200630.xsd EX-101.SCH 57863
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20200630_cal.xml EX-101.CAL 37636
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20200630_def.xml EX-101.DEF 497532
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20200630_lab.xml EX-101.LAB 365075
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20200630_pre.xml EX-101.PRE 514283
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 201104927
SIC: 2835 In Vitro & In Vivo Diagnostic Substances